Search for Severin Schwan and
  1. July 24, 2014

    Roche profit falls as writedown and strong Swiss franc hit group

    Roche posted a 7 per cent fall in net profit in the first half of the year, after the Swiss pharmaceuticals group was hit by...

  2. April 15, 2014

    Roche drug boosts to revenue counteracted by currency’s strength

    Roche’s revenues fell 1 per cent in the first quarter as the strength of the Swiss franc weighed on the pharma group, even...

  1. October 17, 2013

    Roche / Novartis: combination therapy

    Winter might be descending on the Alps, but spring is in the air in Basel. The Swiss city, home to Roche and Novartis, has...

  2. September 30, 2013

    Roche chief Severin Schwan open to co-operation with Novartis

    Roche’s chief executive has signalled openness to renewed co-operation with counterparts at his Swiss rival Novartis, in a...

  3. September 30, 2013

    Europe belt tightening will hit pharma, warns Roche chief

    Europe risks squandering its leading position in the global pharmaceuticals industry because of the “short-term” and...

  4. July 25, 2013

    Roche chief Severin Schwan plays down risk of graft scandal in China

    Roche’s chief executive played down the dangers of the corruption scandal that has embroiled GlaxoSmithKline in China for...

  5. April 11, 2013

    Roche boosted by blockbuster cancer drugs

    Roche kicked off the pharmaceuticals reporting season on a positive note, posting a 6 per cent increase in revenues and...

  6. January 30, 2013

    Roche boosted by robust US sales

    Roche struck a cautious note on its prospects for the coming year as it posted a 4 per cent rise in sales for 2012, with...

  7. October 16, 2012

    Weaker Swiss franc lifts Roche sales

    The weakening Swiss franc has helped Roche to report a 15 per cent rise in third-quarter revenues as the drugmaker announced...

  8. July 26, 2012

    Restructuring costs Roche SFr1.68bn

    Roche, the Swiss pharmaceutical group, maintained its sales targets for 2012, but took SFr1.68bn ($1.72bn) in restructuring...

  9. April 18, 2012

    Roche bid halted by Illumina investors

    Roche, the Swiss drugmaker, said on Wednesday it would let its offer to acquire Illumina expire after shareholders of the US...

  10. April 12, 2012

    Roche persists with Illumina chase

    Roche on Thursday sent its third letter to Illumina shareholders, repeating its readiness to improve its takeover offer, as...

  11. April 7, 2012

    Roche looks at raising bid for Illumina

    Roche, the Swiss drug company, said on Friday it might consider raising its bid to acquire Illumina, the US genetic...

  12. April 2, 2012

    Illumina rejects latest Roche offer

    Roche has reacted angrily to Illumina’s rejection of its improved takeover offer as the rhetoric between the US gene...

  13. March 29, 2012

    Roche / Illumina: time to talk

    Severin Schwan is a determined man. The chief executive of Roche Holding will simply not give up on Illumina. Thursday’s...

  14. March 29, 2012

    Roche improves offer for Illumina

    Roche on Thursday made its long-expected improved cash offer for Illumina with a 15 per cent increase to $51 a share,...

  15. March 20, 2012

    Roche in appeal to Illumina investors

    By Andrew Jack in London and Alan Rappeport in New York Roche has stepped up the pressure on Illumina, the US diagnostics...

  16. February 1, 2012

    Roche steps up Illumina bid as sales hold up

    Roche spotlighted the potential of diagnostics, traditionally the junior of its two divisions, as sales of testing and other...

  17. January 28, 2012

    Investors brace for improved offer from Roche

    Roche this week sought to strengthen its ambitions in “targeted medicine” with a hostile $5.7bn bid for Illumina of the US,...

  18. January 25, 2012

    Roche: bid battle is a gutsy move

    “Screw it, let’s go hostile.” That thought is probably what went through Severin Schwan’s mind last week. The chief...

  19. January 25, 2012

    Pharma groups target specialised deals

    Roche sought to strengthen its position in personalised medicine with a $5.7bn hostile bid early on Wednesday for Illumina...

  20. FT Alphaville

    January 25, 2012

    Roche in $5.7bn hostile bid for Illumina

    Roche, the Swiss drugmaker, has made a $5.7bn hostile offer for Illumina, the US diagnostics company, as part of the...

  21. January 25, 2012

    Roche launches $5.7bn bid for US group

    Roche, the Swiss drugmaker, on Wednesday described its $5.7bn hostile offer for Illumina as “full and fair” and said it had...

  22. October 13, 2011

    Strong franc weighs on Roche sales

    Roche sales fell 15 per cent in the third quarter, as the pharmaceuticals group became the latest Swiss company to report...

  23. September 25, 2011

    Roche to offer discounts to developing nations

    Roche is to set to begin offering substantial discounts in developing countries, marking an important strategic shift for...

  24. July 21, 2011

    Avastin problems weigh on Roche

    Roche raised its earnings growth guidance to 10 per cent for the year, despite posting a 5 per cent drop in net income to...

  25. February 2, 2011

    Roche lifts earnings but faces challenges

    Roche has joined Novartis and AstraZeneca in proposing higher dividends or share buy-backs to boost investor confidence as...

  26. January 18, 2011

    Roche finance chief to exit after 10 years

    Roche, the Swiss pharmaceutical group, on Monday said it would replace Erich Hunziker, its long-standing chief financial...

  27. November 30, 2010

    Incoming Merck chief to focus on pricing

    The incoming head of Merck has pledged to focus on “demonstrating value” in pricing as he oversees the launch of a series of...

  28. November 17, 2010

    Roche to slash staff numbers by 6%

    Roche will cut 4,800 jobs – or 6 per cent of its workforce – to save SFr2.4bn ($2.4bn) a year, as the Swiss pharmaceuticals...

  29. October 25, 2010

    Roche to enter new therapy areas

    Roche is planning a big push to expand its business beyond its historic focus on cancer drugs if results from experimental...

  30. September 3, 2010

    Roche to cut jobs after setbacks for drugs

    Roche on Friday confirmed it would be making significant job cuts to tailor spending to tougher markets, but said details...

  31. July 22, 2010

    Roche plays down US bar on cancer drug

    Roche tried to limit the impact of a US regulatory panel’s recommendation to restrict one of its key cancer drugs, as it...

  32. July 21, 2010

    Roche v the FDA

    Roche is the second European pharmaceutical company in a week to have the US Food and Drug Administration question its...

  33. April 16, 2010

    Boost in sales figures for Roche

    Roche yesterday announced sharply higher sales for the first quarter, as the Swiss pharmaceuticals group benefited from...

  34. February 3, 2010

    Genentech buy-out deal weighs on Roche

    Net profits at Roche fell by 22 per cent to SFr8.51bn ($8bn, €5.77bn) last year, as the Swiss pharmaceutical group was hit...

  35. January 27, 2010

    Dr Vasella prescribes good governance pill to Novartis

    A few years ago, Daniel Vasella surprised staid corporate Switzerland by turning up at the annual Novartis press conference...

  36. January 27, 2010

    Dr Vasella prescribes himself a good governance pill

    A few years ago, Daniel Vasella surprised the normally staid world of corporate Switzerland by turning up at the annual...

  37. January 27, 2010

    Novartis in stealthy pursuit of change

    Daniel Vasella may be among the more youthful chief executives in the international pharmaceutical industry - but he is also...

  38. January 26, 2010

    Novartis in stealthy pursuit of change

    Split decision: corporate governance lobbyists welcomed the resignation of Daniel Vasella (right). Joe Jimenez (left) will...

Search for Severin Schwan and